

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Metis TechBio Co., Ltd.**

**剂泰科技(北京)股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 7666)**

## **CLARIFICATION ANNOUNCEMENT**

This announcement is made by Metis TechBio Co., Ltd. (the “**Company**”) on a voluntary basis.

The Company has recently noted certain media report alleging that the China Securities Regulatory Commission (the “**CSRC**”) has issued supplemental information requests to 38 companies, including the Company.

The Company hereby clarifies and emphasizes that the information in that media report concerning the Company is factually inaccurate and misleading. The Company received the CSRC’s filing notice for the listing of the H shares of the Company (the “**H Shares**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the H Share full circulation on March 17, 2026 and the Company was successfully listed on the main board of the Stock Exchange on May 13, 2026. Since the receipt of the filing notice from CSRC, the Company has not received any notification from the CSRC requesting for supplemental information.

In response to such false information in the media report and the potential damage to the reputation of the Company, the Company reserves any rights to initiate legal proceedings in accordance with the applicable laws and take all necessary legal actions to protect the legitimate rights and interests of the Company.

The Company will make further announcement(s) as and when appropriate in accordance with the requirements of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange, the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and/or other applicable laws and regulations.

**Shareholders, holders of the securities and potential investors are advised not to rely on market rumours in relation to the Company. Any information concerning the Company should only be based on the Company's official announcements. Shareholders, holders of the securities and potential investors are reminded to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Metis TechBio Co., Ltd.**  
**Tsai-Ta Lai**

*Chairman of the Board, executive Director and chief executive officer*

Hong Kong, May 26, 2026

*As at the date of this announcement, the Directors are: (i) Dr. Tsai-Ta Lai, Dr. Hongming Chen and Dr. Wenshou Wang as executive Directors; (ii) Mr. Hantao Huang and Ms. Yuan Gong as non-executive Directors; and (iii) Mr. Frank Yee Chon Lyn, Dr. Jin Li and Dr. Peter Edward Lobie as independent non-executive Directors.*